Crossmark

Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer

Crossref DOI link: https://doi.org/10.1038/s41467-021-25700-6

Published Online: 2021-09-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dang, Fabin https://orcid.org/0000-0002-1954-8231
Nie, Li

Zhou, Jin https://orcid.org/0000-0001-8121-4198
Shimizu, Kouhei https://orcid.org/0000-0001-9523-4296
Chu, Chen https://orcid.org/0000-0001-8084-0867
Wu, Zhong

Fassl, Anne

Ke, Shizhong

Wang, Yuangao

Zhang, Jinfang https://orcid.org/0000-0001-8487-6007
Zhang, Tao

Tu, Zhenbo https://orcid.org/0000-0002-3720-7844
Inuzuka, Hiroyuki

Sicinski, Piotr https://orcid.org/0000-0002-8859-5234
Bass, Adam J. https://orcid.org/0000-0002-8193-4758
Wei, Wenyi https://orcid.org/0000-0003-0512-3811
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Cancer Institute (K99CA263194)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA202634)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50 CA168504)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01 CA250959)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01CA098101)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA229307)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA253027)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA177910)

U.S. Department of Health & Human Services | NIH | National Cancer Institute

U.S. Department of Health & Human Services | NIH | National Cancer Institute

U.S. Department of Health & Human Services | NIH | National Cancer Institute

U.S. Department of Health & Human Services | NIH | National Cancer Institute

U.S. Department of Health & Human Services | NIH | National Cancer Institute

U.S. Department of Health & Human Services | NIH | National Cancer Institute

U.S. Department of Health & Human Services | NIH | National Cancer Institute
License Information

Text and Data Mining valid from 2021-09-10

Version of Record valid from 2021-09-10
More Information

Article History

Received: 5 February 2021

Accepted: 23 August 2021

First Online: 10 September 2021

Competing interests

: P.S. has been a consultant at Novartis, Genovis, Guidepoint, The Planning Shop, ORIC Pharmaceuticals, Syros, and Exo Therapeutics; his laboratory receives research funding from Novartis. W.W. is a co-founder and consultant for the ReKindle Therapeutics. A.J.B. received funding from Merck, Bayer, Novartis, and is an advisor to Earli and Helix Nano and a co-founder of Signet Therapeutics. Other authors declare no competing interests.

Document is current

Any future updates will be listed below